Artivion Inc’s filing revealed that its Officer MARSHALL STANTON acquired Company’s shares for reported $0.44 million on Jun 17 ’25. In the deal valued at $29.50 per share,15,000 shares were bought.
Then, Stanton Marshall S. sold 26,132 shares, generating $743,131 in total proceeds. Upon selling the shares at $28.44, the SVP, Clinical & MD Affair now owns 79,200 shares.
Before that, MARSHALL STANTON bought 26,132 shares. Artivion Inc shares valued at $743,130 were divested by the Officer at a price of $28.44 per share.
Canaccord Genuity initiated its Artivion Inc [AORT] rating to a Buy in a research note published on June 17, 2025; the price target was $35. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in late October with a ‘”a Mkt outperform”‘ rating. Lake Street also remained covering AORT and reiterated its “Buy” recommendation on September 27, 2022. Lake Street started covering the stock on August 08, 2022. It rated AORT as “a Buy”.
Price Performance Review of AORT
On Tuesday, Artivion Inc [NYSE:AORT] saw its stock jump 3.62% to $29.77. Over the last five days, the stock has gained 1.81%. Artivion Inc shares have risen nearly 4.13% since the year began. Nevertheless, the stocks have risen 27.77% over the past one year. While a 52-week high of $32.33 was reached on 01/16/25, a 52-week low of $21.97 was recorded on 04/09/25.
Levels Of Support And Resistance For AORT Stock
The 24-hour chart illustrates a support level at 29.08, which if violated will result in even more drops to 28.38. On the upside, there is a resistance level at 30.23. A further resistance level may holdings at 30.69.
The most recent change occurred on March 03, 2022 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $30 price target.
